CMR Surgical, a global medical technology company, today announces its second-generation surgical robotic platform, Versius Plus, has received 510(k) clearance from the United States Food and Drug Administration (FDA) for cholecystectomy procedures.
View all press releases ~ CMR Surgical has closed a financing round of more than $200 million, backed by existing investors and new investor Trinity Capital~ The latest funding will fuel the global commercialisation of its Versius Surgical Robotic System, particularly in the U.S. market, and support continued investment in surgical robotics innovation~ Versius is … Read more
View all press releases ~ Massimiliano Colella appointed CEO at CMR Surgical, leading the company in its mission to bring the benefits of robotic-assisted minimal access surgery to patients around the world with Versius Press Office +44 (0)1223 755801 [email protected] View Press Kit CMR Surgical (CMR or ‘the Company’), the global surgical robotics business, today … Read more
The U.S. Food and Drug Administration (FDA) has granted CMR Surgical marketing authorization for the Versius Surgical System (Versius) in cholecystectomy, paving the way for the next-generation versatile, adaptable, and digitally driven surgical robot to be introduced in the United States.
CMR Surgical has appointed Markus Bauman as Chief Legal & Business Affairs Officer and will join CMR’s executive leadership team. Michelle Paknad has been appointed as Senior Vice President, Global Business Development.
CMR Surgical appoint Daniel (Dan) Moore, a medical technology veteran, as as Non-Executive Chairman.
